Community Collaboration: Application of CDK 4/6 Inhibitors in the Treatment of HR-Positive/HER2-Negative Early Breast Cancer episode artwork

EPISODE · Mar 28, 2024 · 31 MIN

Community Collaboration: Application of CDK 4/6 Inhibitors in the Treatment of HR-Positive/HER2-Negative Early Breast Cancer

from Keeping Current CME

How do you define high-risk for recurrence in breast cancer? Credit available for this activity expires: [03/27/25] Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1000352?ecd=bdc_podcast_libsyn_mscpedu  

Episode metadata supplied by the publisher feed · Published Mar 28, 2024

Embed this episode

Ready to play

Community Collaboration: Application of CDK 4/6 Inhibitors in the Treatment of HR-Positive/HER2-Negative Early Breast Cancer

0:00 31:38

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Keeping Current CME?

This episode is 31 minutes long.

When was this Keeping Current CME episode published?

This episode was published on March 28, 2024.

Can I download this Keeping Current CME episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!